- Home
- MPB vs GHRS Comparison
MPB vs GHRS Comparison
Compare MPB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- GHRS
- Stock Information
- Founded
- MPB 1868
- GHRS 2018
- Country
- MPB United States
- GHRS Ireland
- Employees
- MPB N/A
- GHRS N/A
- Industry
- MPB Major Banks
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- GHRS Health Care
- Exchange
- MPB Nasdaq
- GHRS Nasdaq
- Market Cap
- MPB 525.0M
- GHRS 462.0M
- IPO Year
- MPB N/A
- GHRS 2021
- Fundamental
- Price
- MPB $29.78
- GHRS $8.99
- Analyst Decision
- MPB Buy
- GHRS Strong Buy
- Analyst Count
- MPB 2
- GHRS 3
- Target Price
- MPB $36.00
- GHRS $35.67
- AVG Volume (30 Days)
- MPB 67.9K
- GHRS 89.4K
- Earning Date
- MPB 01-28-2025
- GHRS 02-27-2025
- Dividend Yield
- MPB 2.68%
- GHRS N/A
- EPS Growth
- MPB 14.41
- GHRS N/A
- EPS
- MPB 2.91
- GHRS N/A
- Revenue
- MPB $173,416,000.00
- GHRS N/A
- Revenue This Year
- MPB N/A
- GHRS N/A
- Revenue Next Year
- MPB $19.26
- GHRS N/A
- P/E Ratio
- MPB $10.26
- GHRS N/A
- Revenue Growth
- MPB 4.93
- GHRS N/A
- 52 Week Low
- MPB $19.20
- GHRS $5.92
- 52 Week High
- MPB $33.87
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- MPB 55.01
- GHRS 58.18
- Support Level
- MPB $28.48
- GHRS $8.02
- Resistance Level
- MPB $29.25
- GHRS $10.23
- Average True Range (ATR)
- MPB 0.70
- GHRS 0.90
- MACD
- MPB 0.23
- GHRS 0.11
- Stochastic Oscillator
- MPB 93.36
- GHRS 62.20
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.